Document is current
Any future updates will be listed below
-
Authors
Wang, Qian
Guo, Yicheng https://orcid.org/0000-0001-5357-660X
Casner, Ryan G.
Yu, Jian
Nair, Manoj S. https://orcid.org/0000-0002-5994-3957
Ho, Jerren
Reddem, Eswar R.
Mellis, Ian A.
Wu, Madeline
Tzang, Chih-Chen https://orcid.org/0009-0007-0499-0274
Hong, Hsiang https://orcid.org/0009-0007-8657-5479
Huang, Yaoxing https://orcid.org/0000-0001-6270-1644
Shapiro, Lawrence
Liu, Lihong
Ho, David D. https://orcid.org/0000-0003-1627-149X
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV019355)
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 23 June 2025
First Online: 4 July 2025
Competing interests
: Q.W., J.Y., R.G.C., Y.G., L.S., L.L., and D.D.H. are inventors on the patent application (WH Ref: 0019240.01338US1) or the provisional patent application (63/619,716) filed by Columbia University for a number of SARS-CoV-2-neutralizing antibodies described in this manuscript. Both sets of applications are under review. D.D.H. is a co-founder of TaiMed Biologics and RenBio, a consultant to WuXi Biologics and Brii Biosciences, and board director for Vicarious Surgical. The remaining authors declare no competing interests.
